Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 2051 Ringwood Avenue SAN JOSE CA 95131 |
Tel: | N/A |
Website: | https://www.ranitherapeutics.com |
IR: | See website |
Key People | ||
Mir Imran Executive Chairman of the Board | Talat Imran Chief Executive Officer, Director | Svai S. Sanford Chief Financial Officer |
Mir Hashim Chief Scientific Officer | Eric Groen General Counsel |
Business Overview |
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company. The Company is focused on advancing technologies to enable the administration of biologics and drugs orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. It has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. The RaniPill GO, is designed to deliver up to a three micrograms (mg) dose of drug with high bioavailability. The capsule includes a coating designed to withstand stomach acid but dissolve in the jejunum portion of the small intestine. Its pipeline includes RT-102, RT-105, RT-111 and RT-110. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC, which is intended to enable delivery of drug payloads up to 200uL in liquid form with high bioavailability. |
Financial Overview |
For the fiscal year ended 31 December 2023, Rani Therapeutics Holdings Inc revenues was not reported. Net loss increased 11% to $34M. Higher net loss reflects Interest expense and other, net increase from $1.1M to $5.1M (expense), Stock-based Compensation in SGA increase of 32% to $12.6M (expense), Research and development - Balancing val increase of 9% to $33.2M (expense). |
Employees: | 140 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $374.58M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$65.28M as of Dec 31, 2023 |
Net annual income (TTM): | -$33.97M as of Dec 31, 2023 |
Free cash flow (TTM): | -$52.47M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 50,157,292 as of Mar 14, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |